Journal
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
Volume 42, Issue 6, Pages 965-974Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.biocel.2010.02.009
Keywords
Intima; Smooth muscle cells; Hyperglycemia; Restenosis; Proliferation
Categories
Funding
- NIH [HL080166, HL074219, HL078663, CA108647]
- American Heart Association [0950118G]
Ask authors/readers for more resources
Atheroma formation and restenosis following percutaneous vascular intervention involve the growth and migration of vascular smooth muscle cells (SMCs) into neointimal lesions, in part due to changes in the extracellular matrix. While some clinical studies have suggested that, in comparison to non-diabetics, beta 3 integrin inhibition in diabetic patients confers protection from restenosis, little is known regarding the role of beta 3 integrin inhibition on SMC responses in this context To understand the molecular mechanisms underlying integrin-mediated regulation of SMC function in diabetes, we examined SMC responses in diabetic mice deficient in integrin beta 3 and observed that the integrin was required for enhanced proliferation, migration and extracellular regulated kinase (ERK) activation Hyperglycemia-enhanced membrane recruitment and catalytic activity of PKC beta in an integrin beta 3-dependent manner Hyperglycemia also promoted SMC filopodia formation and cell migration, both of which required alpha V beta 3, PKC beta, and ERK activity Furthermore, the integrin-kinase association was regulated by the alpha V beta 3 integrin ligand thrombospondin and the integrin modulator Rap1 under conditions of hyperglycemia These results suggest that there are differences in SMC responses to vascular injury depending on the presence or absence of hyperglycemia and that SMC response under hyperglycemic conditions is largely mediated through beta 3 integrin signaling Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available